1. Home
  2. WK vs GPCR Comparison

WK vs GPCR Comparison

Compare WK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workiva Inc.

WK

Workiva Inc.

HOLD

Current Price

$52.17

Market Cap

2.8B

Sector

Technology

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$53.36

Market Cap

2.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WK
GPCR
Founded
2008
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.8B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
WK
GPCR
Price
$52.17
$53.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
12
Target Price
$95.30
$103.17
AVG Volume (30 Days)
946.1K
842.4K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
52.53
N/A
EPS
0.33
N/A
Revenue
$884,568,000.00
N/A
Revenue This Year
$20.85
N/A
Revenue Next Year
$15.43
N/A
P/E Ratio
$158.58
N/A
Revenue Growth
19.75
N/A
52 Week Low
$43.34
$15.80
52 Week High
$97.10
$94.90

Technical Indicators

Market Signals
Indicator
WK
GPCR
Relative Strength Index (RSI) 57.21 64.30
Support Level $51.49 $36.11
Resistance Level $52.20 $57.23
Average True Range (ATR) 2.03 2.65
MACD 0.54 0.44
Stochastic Oscillator 78.36 70.94

Price Performance

Historical Comparison
WK
GPCR

About WK Workiva Inc.

Workiva Inc is an AI-powered platform for trust, transparency, and accountability. Accounting, finance, sustainability, risk, and audit teams rely on Workiva for their mission-critical work. It transforms how customers connect data, unify processes, and empower teams in a secure, AI-powered, audit-ready, collaborative platform. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: